NCT01739192View on ClinicalTrials.gov

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Cocaine Use Disorders
Interventions
DRUG

Bupropion

Subjects will be maintained on oral bupropion or placebo during the study.

Trial Locations (1)

40536-0086

University of Kentucky Medical Center, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Craig Rush

OTHER

NCT01739192 - A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence | Biotech Hunter | Biotech Hunter